Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ALLK

Allakos Inc

Dec 11 • 04:00PM ET

1.04

Dollar change -0.04
Percentage change -3.70	%

Healthcare • Biotechnology • USA • NASD

Peers: RARE CARA ATRA ALLO KPTI BLUE ADAP FATE PBYI EXEL

| Held by: VTI VXF FESM IWC ONEQ BTEC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.03	Insider Own	13.78%	Shs Outstand	89.34M	Perf Week	-7.14%
Market Cap	92.92M	Forward P/E	-	EPS next Y	-0.56	Insider Trans	-0.70%	Shs Float	77.03M	Perf Month	-30.67%
Income	-178.75M	PEG	-	EPS next Q	-0.19	Inst Own	68.30%	Short Float	1.30%	Perf Quarter	73.33%
Sales	0.00M	P/S	-	EPS this Y	29.98%	Inst Trans	-10.61%	Short Ratio	1.52	Perf Half Y	-18.75%
Book/sh	0.81	P/B	1.28	EPS next Y	62.29%	ROA	-87.64%	Short Interest	1.00M	Perf Year	-65.33%
Cash/sh	1.04	P/C	1.00	EPS next 5Y	26.70%	ROE	-121.68%	52W Range	0.54 - 3.40	Perf YTD	-61.90%
Dividend Est.	-	P/FCF	-	EPS past 5Y	0.51%	ROI	-164.81%	52W High	-69.46%	Beta	0.91
Dividend TTM	-	Quick Ratio	6.08	Sales past 5Y	0.00%	Gross Margin	-	52W Low	94.39%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	6.08	EPS Y/Y TTM	-5.32%	Oper. Margin	-	RSI (14)	47.74	Volatility	7.55% 10.04%
Employees	131	Debt/Eq	0.54	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.20	Target Price	3.35
Option/Short	Yes / Yes	LT Debt/Eq	0.49	EPS Q/Q	60.59%	Payout	-	Rel Volume	0.35	Prev Close	1.08
Sales Surprise	-	EPS Surprise	15.36%	Sales Q/Q	-	Earnings	Nov 06 AMC	Avg Volume	660.57K	Price	1.04
SMA20	-1.17%	SMA50	1.47%	SMA200	2.50%	Trades		Volume	276,188	Change	-3.70%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-17-24	Downgrade	Jefferies	Buy → Hold	$6 → $1.50
Jan-16-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-18-23	Upgrade	William Blair	Mkt Perform → Outperform
Dec-08-23	Resumed	Jefferies	Buy	$9 → $6
Sep-27-23	Initiated	JMP Securities	Mkt Outperform	$11
May-12-23	Upgrade	Jefferies	Hold → Buy	$6 → $9
Mar-07-23	Initiated	Piper Sandler	Overweight	$22
Sep-12-22	Downgrade	SMBC Nikko	Neutral → Underperform	$2
Dec-22-21	Downgrade	William Blair	Outperform → Mkt Perform
Dec-22-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$17
Dec-22-21	Downgrade	Jefferies	Buy → Hold
Dec-22-21	Downgrade	Cowen	Outperform → Market Perform
Dec-22-21	Downgrade	BofA Securities	Buy → Underperform	$155 → $12
Aug-26-21	Initiated	Morgan Stanley	Equal-Weight	$88
Jul-15-21	Initiated	Cowen	Outperform
May-18-21	Initiated	H.C. Wainwright	Buy	$230
Feb-24-21	Initiated	Cantor Fitzgerald	Overweight	$218
Jan-15-21	Initiated	BofA Securities	Buy	$145
Dec-21-20	Initiated	SVB Leerink	Outperform	$150
Feb-27-20	Initiated	Barclays	Underweight	$36

Show Previous Ratings

Nov-11-24 12:00PM	All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy (Zacks) +11.11%
Nov-06-24 04:02PM	Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-10-24 04:02PM	Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers (GlobeNewswire)
Aug-07-24 11:54PM	ALLK Stock Earnings: Allakos Beats EPS for Q2 2024 (InvestorPlace) -9.90%
04:02PM	Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
04:02PM	Loading…
Jun-25-24 04:02PM	Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile (GlobeNewswire) -10.17%
May-28-24 07:02AM	Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria (GlobeNewswire)
May-10-24 04:02PM	Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions (GuruFocus.com) -6.98%
May-09-24 10:56PM	ALLK Stock Earnings: Allakos Meets EPS for Q1 2024 (InvestorPlace)
04:02PM	Allakos Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-03-24 07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +5.45%
Apr-09-24 06:31AM	3 Biotech Stocks to Dump Before They Go to Zero (InvestorPlace) +6.19%
Apr-04-24 08:36AM	Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions (Zacks)
Mar-16-24 05:31AM	Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4 (GuruFocus.com)
Mar-14-24 09:54PM	ALLK Stock Earnings: Allakos Misses EPS for Q4 2023 (InvestorPlace) -6.45%
04:02PM	Loading…
04:02PM	Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-26-24 07:02AM	Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024 (GlobeNewswire) +7.35%
Feb-12-24 07:02AM	Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition (GlobeNewswire)
Jan-18-24 09:35AM	Here's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 Weeks (Zacks) +6.86%
Jan-17-24 12:10PM	Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug (Zacks) -14.29%
Jan-16-24 11:36AM	Why Is Allakos (ALLK) Stock Down 57% Today? (InvestorPlace) -60.20%
09:40AM	Is Allakos (ALLK) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:28AM	Allakos drops lead asset after midphase flops join litany of letdowns, halves headcount (FierceBiotech.com)
07:27AM	UPDATE 2-Allakos tumbles after skin disease drug fails mid-stage studies (Reuters)
07:17AM	Allakos says experimental skin disease drug fails mid-stage studies (Reuters)
07:02AM	Allakos Announces a Restructuring to Focus on Development of AK006 (GlobeNewswire)
07:00AM	Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints (GlobeNewswire)
05:09AM	Allakos to lay off half of staff, scrap drug after study setback (BioPharma Dive)
Nov-13-23 05:01PM	Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q3 2023 (GuruFocus.com)
04:02PM	Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
12:10PM	Loading…
Sep-27-23 12:10PM	Why Shares of Allakos Are Up Wednesday (Motley Fool) +15.74%
Aug-30-23 04:05PM	Allakos Appoints Neil Graham to its Board of Directors (GlobeNewswire)
Aug-09-23 04:02PM	Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire) -9.09% -7.96%
Aug-02-23 04:05PM	Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors (GlobeNewswire)
08:20AM	Companies Like Allakos (NASDAQ:ALLK) Are In A Position To Invest In Growth (Simply Wall St.)
Jun-12-23 07:02AM	Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition (GlobeNewswire)
Jun-05-23 07:02AM	Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023 (GlobeNewswire)
May-13-23 08:05AM	Allakos Inc. (NASDAQ:ALLK) has caught the attention of institutional investors who hold a sizeable 45% stake (Simply Wall St.)
May-12-23 05:00PM	Why Allakos Stock Skyrocketed Nearly 9% Higher Today (Motley Fool) +8.89% +9.93%
May-09-23 04:02PM	Allakos Provides Business Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Mar-07-23 04:05PM	Why Allakos Stock Was Heating Up Today (Motley Fool) +21.30% -6.72%
Mar-06-23 04:02PM	Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -6.90%
Jan-26-23 05:33AM	Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value (Simply Wall St.)
Dec-15-22 11:35AM	Is Allakos (NASDAQ:ALLK) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Dec-09-22 12:00PM	Allakos Inc. (ALLK) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Nov-29-22 07:02AM	Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology (GlobeNewswire) +7.88%
Nov-10-22 09:02AM	Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancers 37th Annual Meeting (GlobeNewswire) +5.86%
Nov-07-22 04:05PM	Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire) +15.52%
Oct-14-22 06:35PM	Alkermes, Allakos, and Other Stocks See Action From Activist Investors (Barrons.com) -9.74%
Sep-30-22 11:48AM	3 Healthcare Stocks to Sell Before They Die (InvestorPlace) +9.29%
Sep-24-22 08:32AM	After losing 95% in the past year, Allakos Inc. (NASDAQ:ALLK) institutional owners must be relieved by the recent gain (Simply Wall St.)
Sep-19-22 07:00AM	Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock (GlobeNewswire) +27.51%
Sep-12-22 07:02AM	Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU) (GlobeNewswire)
Sep-09-22 08:47AM	After Disappointing Data, Allakos Discontinues Work On Lirentelimab In Eosinophilic Gastrointestinal Diseases (Benzinga) +5.71%
07:00AM	Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis (GlobeNewswire)
Aug-31-22 02:10PM	Why Allakos Stock Is on Fire Today (Motley Fool) +20.05%
Aug-04-22 04:04PM	Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire) +9.32%
Jul-25-22 04:05PM	Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors (GlobeNewswire)
Jul-08-22 10:18AM	Companies Like Allakos (NASDAQ:ALLK) Could Be Quite Risky (Simply Wall St.)
May-06-22 04:05PM	Allakos Provides Business Update and Reports First Quarter 2022 Financial Results (GlobeNewswire) -5.74%
Apr-28-22 06:00PM	Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know (Zacks)
Apr-19-22 06:15PM	Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know (Zacks)
Apr-12-22 06:15PM	Allakos Inc. (ALLK) Gains As Market Dips: What You Should Know (Zacks)
Apr-09-22 10:03AM	How Much Of Allakos Inc. (NASDAQ:ALLK) Do Institutions Own? (Simply Wall St.)
Mar-28-22 06:15PM	Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know (Zacks)
Mar-22-22 06:15PM	Allakos Inc. (ALLK) Outpaces Stock Market Gains: What You Should Know (Zacks)
Mar-15-22 06:00PM	Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know (Zacks) +10.24%
Mar-07-22 10:39AM	Why Allakos Stock Sank 17.3% in February (Motley Fool)
Mar-03-22 11:05AM	After clinical trial failures, Peninsula drug developer opts to cut 35% of jobs (American City Business Journals)
Mar-01-22 04:05PM	Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Feb-25-22 06:00PM	Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know (Zacks)
Feb-21-22 09:53AM	Allakos (ALLK) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-17-22 02:38AM	Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs Samsara BioCapital (Insider Monkey) -8.28%
Feb-08-22 01:38PM	Handelsbanken Fonder AB Buys FREYR Battery, Pfizer Inc, GXO Logistics Inc, Sells SVB Financial ... (GuruFocus.com)
Feb-07-22 01:38PM	Silvant Capital Management LLC Buys Netflix Inc, Pfizer Inc, Natera Inc, Sells Visa Inc, ... (GuruFocus.com)
Feb-04-22 06:00PM	Allakos Inc. (ALLK) Flat As Market Gains: What You Should Know (Zacks)
Feb-01-22 01:38PM	BCGM Wealth Management, LLC Buys PowerShares QQQ Trust Ser 1, Apple Inc, First Merchants Corp, ... (GuruFocus.com)
08:00AM	Allakos to Host Investor Day on February 15 (GlobeNewswire)
Jan-24-22 06:15PM	Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know (Zacks)
01:53PM	5 Important Investing Lessons From Allakos Price Collapse (InvestorPlace)
Jan-12-22 12:09PM	Allakos Is a Cautionary Tale of Biopharmaceutical Investing (InvestorPlace)
Jan-09-22 06:26AM	We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate (Simply Wall St.)
Jan-06-22 08:17AM	Why Allakos Stock Plummeted 87.5% in the Last Month of 2021 (Motley Fool)
Jan-05-22 06:59AM	After a Clinical-Data Bombshell, Allakos Might Actually Be a Buy (InvestorPlace)
Jan-04-22 10:00AM	Down 86.1% in 4 Weeks, Here's Why Allakos Inc. (ALLK) Looks Ripe for a Turnaround (Zacks) -7.44%
09:40AM	Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year? (Zacks)
Dec-22-21 04:37PM	Peninsula biotech sheds 90% of stock value after drug trials flop (American City Business Journals) -89.87% +22.22%
12:36PM	ALLK Stock Alert: Why Is Allakos Absolutely Plunging Today? (InvestorPlace)
10:41AM	Why Allakos Stock Is Crashing Today (Motley Fool)
09:07AM	Tesla's Rising, but This Nasdaq Biotech Stock Got Absolutely Crushed Wednesday (Motley Fool)
Dec-21-21 07:15PM	Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases (GlobeNewswire)
Dec-20-21 08:32AM	Implied Volatility Surging for Allakos (ALLK) Stock Options (Zacks)
Dec-08-21 07:38PM	Tekla Life Sciences Investors Buys Amgen Inc, Alkermes PLC, Novavax Inc, Sells Moderna Inc, ... (GuruFocus.com)
07:38PM	Tekla Healthcare Investors Buys Amgen Inc, Guardant Health Inc, Icon PLC, Sells Abbott ... (GuruFocus.com)
Nov-30-21 07:00AM	Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma (GlobeNewswire)
Nov-19-21 10:27AM	Ohio Capital Fund to keep using tax credits; Columbus startup Aware a bright spot in portfolio (American City Business Journals)
08:40AM	Do Options Traders Know Something About Allakos (ALLK) Stock We Don't? (Zacks)
Nov-08-21 04:05PM	Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results (GlobeNewswire)
Oct-25-21 08:00AM	Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Systematic Evaluation (GlobeNewswire)
Oct-24-21 03:35PM	Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting (GlobeNewswire)

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tomasi Adam	Officer	Dec 06 '24	Proposed Sale	1.10	21,116	23,219		Dec 06 04:25 PM
Radford Harlan Baird	Officer	Dec 06 '24	Proposed Sale	1.10	13,138	14,447		Dec 06 04:19 PM
Alexander Robert	Officer	Dec 05 '24	Proposed Sale	1.10	32,466	35,765		Dec 05 03:57 PM
Lee Chin Hyok	Officer	Dec 04 '24	Proposed Sale	1.13	10,634	12,029		Dec 04 04:23 PM
Alexander Robert	Officer	Sep 11 '24	Proposed Sale	0.58	37,311	21,805		Sep 11 03:51 PM
Lee Chin Hyok	Officer	Sep 09 '24	Proposed Sale	0.65	45,320	29,336		Sep 09 04:29 PM
Radford Harlan Baird	Officer	Sep 06 '24	Proposed Sale	0.64	13,665	8,808		Sep 06 03:53 PM
Tomasi Adam	Officer	Sep 06 '24	Proposed Sale	0.64	21,961	14,156		Sep 06 03:46 PM
Radford Harlan Baird	Chief Financial Officer	Jun 28 '24	Sale	1.01	87,064	87,935	204,390	Jul 02 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALLK

Allakos Inc

Upgrade your FINVIZ experience